Teacher Retirement System of Texas Buys Shares of 10,243 Capricor Therapeutics Inc (NASDAQ:CAPR)

Teacher Retirement System of Texas bought a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,243 shares of the biotechnology company’s stock, valued at approximately $141,000.

Several other institutional investors also recently modified their holdings of the stock. Intech Investment Management LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter worth $228,000. Swiss National Bank bought a new position in Capricor Therapeutics during the 4th quarter worth $930,000. AlphaQuest LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth about $78,000. Charles Schwab Investment Management Inc. grew its position in shares of Capricor Therapeutics by 51.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock valued at $1,536,000 after buying an additional 37,868 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its stake in shares of Capricor Therapeutics by 52.4% in the fourth quarter. Oppenheimer & Co. Inc. now owns 104,231 shares of the biotechnology company’s stock valued at $1,438,000 after buying an additional 35,823 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Trading Up 2.7 %

Shares of NASDAQ CAPR opened at $9.74 on Thursday. The firm has a market capitalization of $444.88 million, a P/E ratio of -9.19 and a beta of 4.09. The firm’s 50-day moving average price is $13.72 and its 200-day moving average price is $15.03. Capricor Therapeutics Inc has a 1-year low of $3.52 and a 1-year high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. Equities research analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.